NZ598643A - Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs - Google Patents
Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugsInfo
- Publication number
- NZ598643A NZ598643A NZ598643A NZ59864310A NZ598643A NZ 598643 A NZ598643 A NZ 598643A NZ 598643 A NZ598643 A NZ 598643A NZ 59864310 A NZ59864310 A NZ 59864310A NZ 598643 A NZ598643 A NZ 598643A
- Authority
- NZ
- New Zealand
- Prior art keywords
- thioxoimidazolidin
- benzonitrile
- pyridin
- oxo
- trifluoromethyl
- Prior art date
Links
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- RHOBTDQBNZMQNA-UHFFFAOYSA-N 4-[3-[(6-imidazol-1-ylpyridin-3-yl)methyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound S=C1N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C(=O)C(C)(C)N1CC(C=N1)=CC=C1N1C=CN=C1 RHOBTDQBNZMQNA-UHFFFAOYSA-N 0.000 abstract 1
- KUHRTZWWSAPQNC-UHFFFAOYSA-N 4-[3-[[6-(2-methoxyethoxy)pyridin-3-yl]methyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound C1=NC(OCCOC)=CC=C1CN1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S KUHRTZWWSAPQNC-UHFFFAOYSA-N 0.000 abstract 1
- UTFFSCUWBSEINO-UHFFFAOYSA-N 4-[4,4-dimethyl-3-[[6-(2-methylmorpholin-4-yl)pyridin-3-yl]methyl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound C1COC(C)CN1C(N=C1)=CC=C1CN1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S UTFFSCUWBSEINO-UHFFFAOYSA-N 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 150000002540 isothiocyanates Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- -1 thiohydantoin compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075421 | 2009-09-11 | ||
| EP10075069 | 2010-02-17 | ||
| PCT/EP2010/005297 WO2011029537A1 (en) | 2009-09-11 | 2010-08-28 | Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598643A true NZ598643A (en) | 2013-10-25 |
Family
ID=42782041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598643A NZ598643A (en) | 2009-09-11 | 2010-08-28 | Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20120251551A1 (en:Method) |
| EP (1) | EP2475653A1 (en:Method) |
| JP (1) | JP2013504523A (en:Method) |
| KR (1) | KR20120065396A (en:Method) |
| CN (1) | CN102639523A (en:Method) |
| AR (1) | AR078166A1 (en:Method) |
| AU (1) | AU2010294588A1 (en:Method) |
| BR (1) | BR112012005526A2 (en:Method) |
| CA (1) | CA2773591A1 (en:Method) |
| CL (1) | CL2012000623A1 (en:Method) |
| CO (1) | CO6511228A2 (en:Method) |
| CR (1) | CR20120113A (en:Method) |
| CU (1) | CU20120042A7 (en:Method) |
| DO (1) | DOP2012000063A (en:Method) |
| EA (1) | EA201200473A1 (en:Method) |
| EC (1) | ECSP12011716A (en:Method) |
| IL (1) | IL218390A0 (en:Method) |
| IN (1) | IN2012DN02081A (en:Method) |
| MA (1) | MA33566B1 (en:Method) |
| MX (1) | MX2012002977A (en:Method) |
| NZ (1) | NZ598643A (en:Method) |
| PE (1) | PE20121180A1 (en:Method) |
| PH (1) | PH12012500497A1 (en:Method) |
| SG (1) | SG178919A1 (en:Method) |
| TN (1) | TN2012000108A1 (en:Method) |
| TW (1) | TW201111378A (en:Method) |
| UY (1) | UY32882A (en:Method) |
| WO (1) | WO2011029537A1 (en:Method) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2540728T3 (pl) | 2010-02-17 | 2019-09-30 | Takeda Pharmaceutical Company Limited | Związek heterocykliczny |
| WO2011150457A2 (en) * | 2010-06-01 | 2011-12-08 | The University Of Queensland | Haematopoietic-prostaglandin d2 synthase inhibitors |
| SI2794627T1 (sl) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AR091156A1 (es) | 2012-05-25 | 2015-01-14 | Jansen R & D Ireland | Nucleosidos de espirooxetano de uracilo |
| TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物 |
| SG11201504554UA (en) | 2012-12-21 | 2015-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| CN104341351B (zh) * | 2013-07-30 | 2018-02-06 | 北京海美源医药科技有限公司 | 一种二芳基硫代乙内酰脲衍生物及其应用 |
| DK3080100T3 (da) * | 2013-12-11 | 2023-02-06 | Celgene Quanticel Res Inc | Hæmmere af lysinspecifik demethylase-1 |
| US20160318897A1 (en) | 2013-12-18 | 2016-11-03 | Basf Se | Azole compounds carrying an imine-derived substituent |
| US9682960B2 (en) * | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| CN103896847B (zh) * | 2014-04-09 | 2016-01-20 | 沈江 | 一种非甾体类抗雄激素化合物及其制备方法和应用 |
| EP3140300B1 (en) | 2014-05-07 | 2019-08-14 | Evotec International GmbH | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| CN106187905B (zh) * | 2015-05-05 | 2020-02-21 | 北京海步医药科技股份有限公司 | 丁鲁他胺的结晶形式及其制备方法 |
| CA3001085A1 (en) | 2015-10-08 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Novel modified macrocyclic compounds |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| WO2018177889A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| WO2018177899A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| CN110770210A (zh) | 2017-05-18 | 2020-02-07 | Pi工业有限公司 | 新颖的脒化合物 |
| JP7280286B2 (ja) | 2018-02-13 | 2023-05-23 | バイエル アクチェンゲゼルシャフト | びまん性大細胞型ｂ細胞リンパ腫を治療するための５－フルオロ－４－（４－フルオロ－２－メトキシフェニル）－ｎ－｛４－［（ｓ－メチルスルホンイミドイル）メチル］ピリジン－２－イル｝ピリジン－２－アミンの使用 |
| CA3132963A1 (en) * | 2019-04-11 | 2020-10-15 | University Of Miami | Improved inhibitors of the notch transcriptional activation complex and methods for use of the same |
| US20230135524A1 (en) * | 2020-01-21 | 2023-05-04 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Aryl hydantoin heterocycles and methods of use |
| CN117120436A (zh) * | 2021-03-30 | 2023-11-24 | 苏州开拓药业股份有限公司 | 一种一步法合成乙内酰硫脲衍生物的方法 |
| WO2025103470A1 (zh) * | 2023-11-17 | 2025-05-22 | 中国药科大学 | 作为雄激素受体(ar)拮抗剂的化合物及其应用 |
| CN120309588B (zh) * | 2025-06-10 | 2025-08-12 | 上海健康医学院 | 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2693461B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| USRE35956E (en) | 1991-01-09 | 1998-11-10 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
| FR2716110B1 (fr) | 1994-02-16 | 1996-04-05 | Roussel Uclaf | Compositions cosmétiques ou pharmaceutiques comprenant des liposomes. |
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| ATE384048T1 (de) | 1998-09-22 | 2008-02-15 | Astellas Pharma Inc | Cyanophenyl-derivate |
| US6472415B1 (en) | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
| US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| AU2003216581A1 (en) | 2002-04-12 | 2003-10-27 | Pfizer Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
| CA2529292A1 (en) | 2003-07-02 | 2005-01-20 | Merck & Co., Inc. | Oxazolidinone antibiotics and derivatives thereof |
| BRPI0414918A (pt) | 2003-09-30 | 2006-11-07 | Janssen Pharmaceutica Nv | compostos de benzoimidazola |
| US8247576B2 (en) | 2003-12-23 | 2012-08-21 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
| DE602005027213D1 (de) | 2004-08-03 | 2011-05-12 | Chugai Pharmaceutical Co Ltd | Neue imidazolidinderivate |
| EP1790640A4 (en) * | 2004-09-09 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF |
| ES2343812T3 (es) | 2004-12-03 | 2010-08-10 | F. Hoffmann-La Roche Ag | Derivados de piperidina 3-sustituidos como antagonistas del receptor h3. |
| CN116003328A (zh) * | 2005-05-13 | 2023-04-25 | 加利福尼亚大学董事会 | 二芳基乙内酰脲化合物 |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| KR20160027254A (ko) | 2006-03-29 | 2016-03-09 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴티오히단토인 화합물 |
| CA2703635C (en) | 2007-10-26 | 2017-06-27 | Michael E. Jung | Diarylhydantoin compounds as androgen receptor modulators |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
-
2010
- 2010-08-19 TW TW099127804A patent/TW201111378A/zh unknown
- 2010-08-28 NZ NZ598643A patent/NZ598643A/xx not_active IP Right Cessation
- 2010-08-28 US US13/394,536 patent/US20120251551A1/en not_active Abandoned
- 2010-08-28 JP JP2012528249A patent/JP2013504523A/ja not_active Withdrawn
- 2010-08-28 CN CN2010800508678A patent/CN102639523A/zh active Pending
- 2010-08-28 EA EA201200473A patent/EA201200473A1/ru unknown
- 2010-08-28 CA CA2773591A patent/CA2773591A1/en not_active Abandoned
- 2010-08-28 BR BR112012005526A patent/BR112012005526A2/pt not_active Application Discontinuation
- 2010-08-28 SG SG2012014262A patent/SG178919A1/en unknown
- 2010-08-28 IN IN2081DEN2012 patent/IN2012DN02081A/en unknown
- 2010-08-28 MX MX2012002977A patent/MX2012002977A/es active IP Right Grant
- 2010-08-28 EP EP10747836A patent/EP2475653A1/en not_active Withdrawn
- 2010-08-28 PE PE2012000315A patent/PE20121180A1/es not_active Application Discontinuation
- 2010-08-28 AU AU2010294588A patent/AU2010294588A1/en not_active Abandoned
- 2010-08-28 WO PCT/EP2010/005297 patent/WO2011029537A1/en active Application Filing
- 2010-08-28 KR KR1020127009224A patent/KR20120065396A/ko not_active Withdrawn
- 2010-08-28 PH PH1/2012/500497A patent/PH12012500497A1/en unknown
- 2010-09-08 UY UY0001032882A patent/UY32882A/es not_active Application Discontinuation
- 2010-09-10 AR ARP100103311A patent/AR078166A1/es unknown
-
2012
- 2012-02-29 IL IL218390A patent/IL218390A0/en unknown
- 2012-03-08 MA MA34666A patent/MA33566B1/fr unknown
- 2012-03-08 TN TNP2012000108A patent/TN2012000108A1/en unknown
- 2012-03-09 EC ECSP12011716 patent/ECSP12011716A/es unknown
- 2012-03-09 DO DO2012000063A patent/DOP2012000063A/es unknown
- 2012-03-09 CU CU20120042A patent/CU20120042A7/es unknown
- 2012-03-09 CO CO12041855A patent/CO6511228A2/es not_active Application Discontinuation
- 2012-03-09 CR CR20120113A patent/CR20120113A/es unknown
- 2012-03-09 CL CL2012000623A patent/CL2012000623A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12012500497A1 (en) | 2012-10-22 |
| CL2012000623A1 (es) | 2012-09-14 |
| TW201111378A (en) | 2011-04-01 |
| UY32882A (es) | 2011-04-29 |
| EA201200473A1 (ru) | 2012-10-30 |
| CN102639523A (zh) | 2012-08-15 |
| AU2010294588A1 (en) | 2012-04-05 |
| US20120251551A1 (en) | 2012-10-04 |
| KR20120065396A (ko) | 2012-06-20 |
| BR112012005526A2 (pt) | 2016-04-26 |
| TN2012000108A1 (en) | 2013-09-19 |
| EP2475653A1 (en) | 2012-07-18 |
| WO2011029537A1 (en) | 2011-03-17 |
| ECSP12011716A (es) | 2012-04-30 |
| CO6511228A2 (es) | 2012-08-31 |
| IL218390A0 (en) | 2012-04-30 |
| CR20120113A (es) | 2012-05-02 |
| PE20121180A1 (es) | 2012-08-24 |
| CU20120042A7 (es) | 2012-06-21 |
| AR078166A1 (es) | 2011-10-19 |
| DOP2012000063A (es) | 2012-05-15 |
| IN2012DN02081A (en:Method) | 2015-08-21 |
| MX2012002977A (es) | 2012-04-30 |
| SG178919A1 (en) | 2012-04-27 |
| CA2773591A1 (en) | 2011-03-17 |
| JP2013504523A (ja) | 2013-02-07 |
| MA33566B1 (fr) | 2012-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598643A (en) | Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs | |
| PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
| WO2013184480A3 (en) | Processes to produce certain 2-(pyridine-3-yl)thiazoles | |
| MX2012002217A (es) | Compuestos heterociclicos como inhibidores de cinasa janus. | |
| NZ596826A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| NZ711976A (en) | Processes and intermediates for making a jak inhibitor | |
| PH12014500842A1 (en) | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection | |
| MX342850B (es) | Proceso para la preparacion de triazolonas quirales. | |
| NZ596117A (en) | Novel anti-inflammatory agents | |
| TW200800997A (en) | Chemical compounds | |
| MY162022A (en) | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | |
| MX347619B (es) | Polimorfos y sales de 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-p iperazinil] metil}-1,3-oxazol-2-il)-1h-indazol como inhibidores de pi3k para usarse por ejemplo en el tratamiento de trastornos respiratorios. | |
| WO2010144499A3 (en) | Urea derivatives as kinase inhibitors | |
| EP2509445A4 (en) | METHOD FOR PRODUCING STABLE STRENGTH DISPERSIONS | |
| WO2011089234A3 (en) | Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease | |
| WO2012028925A3 (en) | Process for the preparation of telmisartan | |
| PH12015500160A1 (en) | Method of producing 4-[5-(pyridin-4-yl)-1h-1,2,4-triazole-3-yl]pyridin-2-carbonitrile, and intermediary thereof | |
| TW200710084A (en) | Process for the synthesis of organic compounds | |
| MX353203B (es) | Metodo para producir un derivado heterociclico fenilo sustituido por medio del metodo de acoplamiento utilizando un compuesto paladio. | |
| MX2011008348A (es) | Proceso para producir derivado heterociclico sustituido con fenilo a traves de acoplamiento usando catalizador de metal de transicion. | |
| NZ595660A (en) | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | |
| MY150817A (en) | Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid | |
| WO2012025935A3 (en) | Process for preparing 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparing deferasirox | |
| EP2952501A3 (en) | Anti-cancer dibenzocycloheptane derivatives and a catalytic method for dibenzocycloheptane synthesis and allocolchicinoid synthesis | |
| NZ598693A (en) | Maleic acid salt and crystal thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |